GCDCA通过S1PR2/PI3K/AKT介导的M2型巨细胞的极化促进肝细胞癌的进展
Mengmeng Xue1,2,3, Wei Yu3, Kuizhi Zhang1,2,3
1School of Pharmacy, Anhui Medical University, Hefei, China.
Frontiers in immunology
|March 11, 2026
概括
甘油脱氧胆酸 (GCDCA) 通过重编程巨细胞来促进肝细胞癌 (HCC). 这种胆汁酸激活S1PR2/PI3K/AKT通路,增强M2巨细胞极化和瘤微环境中的癌症干细胞干性.
科学领域:
- 肝胆道癌症 肝胆道癌症
- 癌症免疫学 癌症免疫学
- 分子瘤学分子瘤学
背景情况:
- 胆酸代谢障碍与肝细胞癌 (HCC) 的发展有关.
- 瘤微环境 (TME) 中的瘤相关巨细胞 (TAM) 关键调节HCC的进展,入侵和免疫逃避.
- 葡萄糖基二氧化醇酸 (GCDCA) 影响TME并驱动HCC的精确机制在很大程度上仍未定义.
研究的目的:
- 调查GCDCA在HCC进展中的作用.
- 阐明GCDCA对瘤微环境 (TME) 和癌症干细胞 (CSC) 的影响.
- 确定参与GCDCA介导的HCC进展的分子途径.
主要方法:
- 单细胞测序以识别TME内的恶性CSC亚群.
- 在体内研究使用原发性肝癌模型来评估GCDCA效应.
- 涉及巨细胞和瘤细胞系统的机制研究,以探索S1PR2/PI3K/AKT信号通路.
主要成果:
- 单细胞测序发现了一个高度恶性的CSC亚群.
- 在体内,GCDCA的干预加速了肝癌的进展,并增强了CSC的干.
- 在巨细胞上,GCDCA激活了S1PR2,启动了S1PR2/PI3K/AKT通路,并促进了M2极化,从而支持了CSC生长.
结论:
- 通过S1PR2/PI3K/AKT通路诱导M2巨细胞极化,GCDCA促进HCC,从而增强瘤细胞干性.
- 这项研究揭示了胆酸介导的TME重塑在肝癌中的新机制.
- 鉴定的途径为HCC治疗提供了潜在的治疗点.
相关概念视频
GPCRs Regulate Adenylyl Cylase Activity
8.0K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
8.0K
mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
The Ras Gene
7.4K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.4K
PI3K/mTOR/AKT Signaling Pathway
6.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.1K
MAPK Signaling Cascades
9.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.0K
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K


